Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

Popovic, Djordje S.; Παπάνας, Νικόλαος; Stoian, Anca Pantea; Rizvi, Ali A.; Rizzo, Manfredi

doi:10.1007/s13300-021-01170-3

Cited by 15 publications

(22 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, careful and proper management of patients with diabetes is mandatory during the COVID-19 era, to minimize the deleterious effects of the pandemic on this category of high-risk subjects, and to promote the use of existing antidiabetic medications with proven cardiometabolic benefits [80][81][82][83].…”

Section: Bidirectional Impact Of Covid-19 and Diabetesmentioning

confidence: 99%

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Kapoor

Kalra²,

Mahmeed³

et al. 2022

Diabetes Ther

Self Cite

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been shown to disrupt many organ systems in the human body. Though several medical disorders have been affected by this infection, a few illnesses in addition may also play a role in determining the outcome of COVID-19. Obesity is one such disease which is not only affected by the occurrence of COVID-19 but can also result in a worse clinical outcome of COVID-19 infection. This manuscript summarizes the most recent evidence supporting the bidirectional impact of COVID-19 and obesity. It highlights how the presence of obesity can be detrimental to the outcome of COVID-19 in a given patient because of the mechanical limitations in lung compliance and also by the activation of several thrombo-inflammatory pathways. The sociodemographic changes brought about by the pandemic in turn have facilitated the already increasing prevalence of obesity. This manuscript highlights the importance of recognizing these pathways which may further help in policy changes that facilitate appropriate measures to prevent the further worsening of these two pandemics.

show abstract

Section: Bidirectional Impact Of Covid-19 and Diabetesmentioning

confidence: 99%

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Kapoor

Kalra²,

Mahmeed³

et al. 2022

Diabetes Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Insights and lessons from this experience can guide us to better manage cardiometabolic risk and overcoming current challenges [ 114 , 115 ]. In this context, the action and the effects of distinct antidiabetic drugs, including MTF, have been extensively investigated over the last two years [ 116 , 117 ], as well as the impact of genetics, comorbidities and inflammation on gender differences in COVID-19 outcomes [ 118 ].…”

Section: Sex/gender Differences Using Mtfmentioning

confidence: 99%

Metformin: Sex/Gender Differences in Its Uses and Effects—Narrative Review

Ilias¹,

Rizzo

Zabulienė

2022

Medicina

Self Cite

View full text Add to dashboard Cite

Metformin (MTF) occupies a major and fundamental position in the therapeutic management of type 2 diabetes mellitus (T2DM). Gender differences in some effects and actions of MTF have been reported. Women are usually prescribed lower MTF doses compared to men and report more gastrointestinal side effects. The incidence of cardiovascular events in women on MTF has been found to be lower to that of men on MTF. Despite some promising results with MTF regarding pregnancy rates in women with PCOS, the management of gestational diabetes, cancer prevention or adjunctive cancer treatment and COVID-19, most robust meta-analyses have yet to confirm such beneficial effects.

show abstract

“…The need to face these two pandemics simultaneously raised interest in analysing the complex interaction between the use of antidiabetic agents and COVID-19, beginning from the molecular mechanisms involved in the virus adhesion, in the host’s cell’s inflammatory response, in the secondary organ damage and leading to treatment strategies and clinical outcomes [ 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19

Salmen

Pietroșel²,

Mihai

et al. 2022

Biomedicines

View full text Add to dashboard Cite

The present study aimed to analyse the published data and to realize an update about the use and pathogenesis of the novel antidiabetic drugs, respectively, dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 Ra), and sodium-glucose co-transporter-2 inhibitors (SGLT-2i), in patients with type 2 diabetes mellitus (T2DM) and coronavirus disease (COVID-19). Literature research in the PubMed and Web of Science database was performed in order to identify relevant published clinical trials and meta-analyses that include information about the treatment with novel antidiabetic agents in patients with T2DM and COVID-19. A total of seven articles were included, and their primary and secondary outcomes were reported and analysed. DPP-4i has mixed results on mortality in T2DM patients with COVID-19 but with an overall slightly favourable or neutral effect, whereas GLP-1 Ra seems to have a rather beneficial impact, while SGLT-2i may be useful in acute illness. Even if there are limited data, they seem to have favourable efficacy and safety profiles. The available evidence is heterogenous and insufficient to evaluate if the benefits of non-insulin novel antidiabetic drugs in COVID-19 treatment are due to the improvement of glycaemic control or to their intrinsic anti-inflammatory effects but highlights their beneficial effects in the pathogenesis and evolution of the disease.

show abstract

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

Cited by 15 publications

References 72 publications

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Metformin: Sex/Gender Differences in Its Uses and Effects—Narrative Review

Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19

Contact Info

Product

Resources

About